Demcon invests in CryoSol technology for acceleration of research into ‘major’ diseases

Technology developer and producer Demcon contributes towards a new technology that can accelerate research into major diseases such as cancer, Alzheimer’s, tuberculosis and Aids. This concerns a new appliance, the VitroJet, for freezing preparations with better quality and a higher yield. Demcon provides for the engineering and production of the VitroJet and invests in CryoSol-World, the spin-off of the University of Maastricht which will launch the VitroJet in the market next year. “We want our contribution to support the scientists who have to develop new treatments for these diseases in the coming years.” Read more...